SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease

Résumé fourni par la source

Parkinson’s disease (PD) is one of the most common neurological disorder diseases which takes place when brain cells gradually die. PD is considered a challengeable disease because of the similarities between PD and other brain disorders. For this reason, there are several ways to diagnose PD. Nuclear medicine can be a solution to distinguish the similarities between some brain disorders and PD. The aim of this review is to understand the differences between three radiopharmaceuticals used to diagnose PD and to list the advantages and disadvantages of using each radiopharmaceutical. This review includes studies from 2014 to 2019. Every study published before 2014 was excluded. The database used for this search was found in PubMed. English filters and best matches were used to minimize the outcomes. The comparison between PD nuclear medicine agents was established according to three main points: availability and the length of the scan, sensitivity and specificity, and visual evolution. It would appear that using TRODAT 99mTc can be helpful for some departments that other agents cannot offer, especially 123I. However, using MIBG as a biomarker increases the specificity in some studies. MIBG 123I can be used with TRODAT 99mTc as a biomarker. Moreover, applying PET/CT agents can be studied and researched along with nuclear medicine agents. More research studies are needed to understand the relation between cardiac uptake and PD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.